Cardiff Oncology, Inc.
CRDF· Nasdaq
CRDFCardiff Oncology, Inc.
Released May 6, 2021, after the close
10-Q filed May 6, 2021, 36 days after period end · 0001628280-21-009283
| Metric | Q1 2021 | Q1 2020 | Q1 2019 | Q1 2018 |
|---|---|---|---|---|
| Revenue | $72.00K | $68.00K | $62.02K | $100.14K |
| Net Income | -$5.18M | -$4.09M | -$3.90M | -$4.79M |
| EPS Diluted |
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
| -$0.14 |
| -$0.41 |
| -$1.02 |
| -$6.23 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
